Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemzoparlimab in R/R Multiple Myeloma
NCT04895410Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of lemzoparlimab in multiple myeloma (MM) (9 arms), sponsored by AbbVie Inc. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Jan 2022; status: terminated.
02
Drugs
lemzoparlimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04895410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895410.